MedPath

The Artificial Saliva Spray Reduces Xerostomia in Diabetes Type II

Not Applicable
Completed
Conditions
Xerostomia Due to Hyposecretion of Salivary Gland
Diabetes Mellitus, Type 2
Interventions
Device: artificial saliva spray (AS)
Other: maritime throat spray (TT)
Registration Number
NCT03452085
Lead Sponsor
Certmedica International GmbH
Brief Summary

In diabetes Type II the xerostomia is a quite frequent symptom. In evaluating the activity of an artificial saliva spray compared to a water gel in patients with Diabetes Type II patients had to follow a three day treatment with each product. Whereas after the first treatment period the two groups had to follow a wash out period of three days before the second treatment period could begin.

The artificial saliva spray reduced the xerostomia and the inflammation or the oral tissue.

Detailed Description

In diabetes Type II the xerostomia is a quite frequent symptom. The trial was conducted at a single center. Designed and implementing UNI EN ISO 14155:2012, STROBE statement Version 4 and was in conformity with the guidelines of the Declaration of Helsinki.

The type of study was a randomized, cross over clinical trial to compare two treatments (artificial saliva spray (aldiamed(R) mouth spray) AS vs. (Tonimer(R) Throat Spray) TT .

Twenty one subjects that were part of the epidemiological screening for asymptomatic vascular diseases conducted in the Irwin Lab3 of Spoltore (PE / Italy) The degree of xerostomia for the admission had to be at least \> 2 according to a semi-quantal scale (ranging from 0 to 6) and patients already under treatment for xerostomia or with xerostomia score \< 2, suffering from obesity, cancer, drug addiction or alcoholism were excluded.

The patients had to follow a three day treatment with each product. Whereas after the first treatment period the two groups had to follow a wash out period of three days before the second treatment period could begin.

The study consisted of a preliminary selection during screening, the measurement of xerostomia and random allocation, first treatment period, wash out period and finally the second treatment period.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
21
Inclusion Criteria
  • suffering xerostomia
  • degree of xerostomia at least > 2 according to a semiquantal scare ranging from 0 to 6
  • diabetes Type II > one year, with stabilized oral hypoglycemic therapy from at least 6 months.
  • concomitant chronic diseases pertaining to dyslipidemia, cardiovascular and/or gastrointestinal diseases, and anxiety/depression were accepted provided under adequate therapy since at least 6 months.
Exclusion Criteria
  • under treatment for xerostomia or with xerostomia score < 2
  • suffering from obesity (BMI > 30 kg/m2),
  • cancer of any type
  • drug addiction and alcoholism

Study & Design

Study Type
INTERVENTIONAL
Study Design
CROSSOVER
Arm && Interventions
GroupInterventionDescription
maritime throat spray (TT)artificial saliva spray (AS)The randomized part of the participants who started first with the marine water throat spray taking it three times a day for a three days treatment, followed by a wash out phase of 3 days. After wash out phase they take for three days the artificial saliva spray taking it three times a day for a three days treatment.
artificial saliva spray (AS)maritime throat spray (TT)The randomized part of the participants who started first with the artificial saliva spray taking it three times a day for a three days treatment, followed by a wash out phase of 3 days. After wash out phase they take for three days the marine water throat spray taking it three times a day for a three days treatment.
artificial saliva spray (AS)artificial saliva spray (AS)The randomized part of the participants who started first with the artificial saliva spray taking it three times a day for a three days treatment, followed by a wash out phase of 3 days. After wash out phase they take for three days the marine water throat spray taking it three times a day for a three days treatment.
maritime throat spray (TT)maritime throat spray (TT)The randomized part of the participants who started first with the marine water throat spray taking it three times a day for a three days treatment, followed by a wash out phase of 3 days. After wash out phase they take for three days the artificial saliva spray taking it three times a day for a three days treatment.
Primary Outcome Measures
NameTimeMethod
xerostomiafirst day before treatment; change to third day after treatment (day 1+3; 7+9)

xerostomia was measured according to a semi-quantal visual scale (or VAS; visual analogue scale) ranging from 0 to 6 with intervals of 1 point

Secondary Outcome Measures
NameTimeMethod
stimulated salivary flowfirst day before treatment; change to third day after treatment (day 1+3; 7+9)

Subject was asked to chew a standard square of medical cotton for one minute rolling the cotton in the mouth in order to collect the saliva. The measure of the flow consisted in weighing the cotton before and after the chewing

antioxidant capacity of saliva (SAT test)first day before treatment; changes to third day after treatment (day 1+3; 7+9)

The test utilizes the capacity of thiocyanate (SCN) to react with iron (Fe3+) causing the formation of FE((SCN)6)3-.

patients preference for treatment AS or TTthird day after finalization of the treatment period (day 3; 9)

question in regard to the preference

Trial Locations

Locations (1)

Irwin Labs, University of Chieti

🇮🇹

Chieti, PE, Italy

© Copyright 2025. All Rights Reserved by MedPath